|

Ablation of Consecutive Atrial Tachycardia

RECRUITINGN/ASponsored by Evangelical Hospital Düsseldorf
Actively Recruiting
PhaseN/A
SponsorEvangelical Hospital Düsseldorf
Started2020-12-22
Est. completion2027-06
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery
* Surface ECG-documentation of AT as primary clinical arrhythmia
* ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms

Exclusion Criteria:

* \< 18 years
* No previous atrial fibrillation ablation procedure or cardiac surgery
* Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment
* History of hemorrhagic diathesis or other coagulopathies
* Contraindications for oral anticoagulation
* Hyper- or hypothyroidism
* Has any condition that would make participation not be in the best interest of the subject

Conditions5

Arrhythmias, CardiacAtrial TachycardiaHeart ArrhythmiaHeart DiseaseHeart Diseases

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.